CureVac Establishes European-Based Network to Ramp Up Manufacturing of its COVID-19 Vaccine Candidate, CVnCoV
- Building an integrated European vaccine manufacturing network with experienced partners
- Managing supply chain risk by collaborating with several partners for each manufacturing step
- Increasing capacity to reach up to 300 million doses in 2021 and up to 600 million doses in 2022
CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced today that it is accelerating the expansion of its manufacturing network to deliver pandemic-scale volumes of its COVID-19 vaccine candidate, CVnCoV. Preparations for the start of production and required technology transfers are underway.